13D·WATCH Activist + Insider Intelligence Live feed Blog About Pricing
SC Filed 2018-01-04 Event — SEC 0001382333-18-000003 →

Meditor Group Ltd → EXELIXIS, INC. EXEL

Stake: — Shares: —
Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 25/100
  • Passive Schedule 13G filer baseline
  • Held by 1 tracked 13F institutional manager
  • Elevated short days-to-cover (11.3 DTC)

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)
1 transaction
0 buys · 1 sales · 0 awards/exercises
Issuer Cluster
6 13D/G filings on this issuer
5 other filings besides this one
Filer Track Record
3 filings by this filer
2 other filings in the data moat
Short Interest · settle 2026-10-15
DTC 11.33
27,313,139 shares short · -3.1% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers
1 holder · $37.52M
Point72 Asset Mgmt

Form 4 Insider Transactions · last 365d

DateInsiderRoleTypeSharesPriceValue
2026-08-10 Beckerle Mary C director Sale 9,812 $53.66 $527K

Other 13D/G Filings on EXELIXIS, INC.

FiledFormFilerStakeShares
2026-08-14 SCHEDULE 13D/A FARALLON CAPITAL MANAGEMENT, L.L.C. 5.60% 13,989,010 view →
2026-01-05 SCHEDULE Farallon Capital Partners, L.P. 5.90% 15,709,500 view →
2025-05-20 SCHEDULE Farallon Capital Partners, L.P. 6.80% 18,635,500 view →
2025-03-05 SCHEDULE Farallon Capital Partners, L.P. 8.40% 23,439,500 view →
2023-06-02 SC Caligan Partners LP — — view →

Other Filings by Meditor Group Ltd

FiledFormIssuerStakeShares
2024-01-03 SC Esperion Therapeutics, Inc. ESPR — — view →
2018-01-03 SC Esperion Therapeutics, Inc. ESPR — — view →

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →